Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Daratumumab Quadruplet Improves Hematologic CR Rate in AL Amyloidosis

December 7th 2020

December 7, 2020 - The addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to improved hematologic complete response rate compared with VCd alone in patients with newly diagnosed amyloid light-chain amyloidosis.

Panobinostat/Subcutaneous Bortezomib Triplet at Higher Dosing Schedules Shows Favorable Outcomes in Relapsed/Refractory Myeloma

December 7th 2020

Panobinostat, given at a 20-mg 3-times-weekly or twice-weekly dosing schedule, in combination with subcutaneous bortezomib and dexamethasone showed durable responses and an acceptable safety profile in patients with relapsed or relapsed/refractory myeloma.

Encouraging Efficacy Shown With Luspatercept in MDS/MPN-RS-T

December 7th 2020

December 7, 2020 — Findings from the MEDALIST trial demonstrated encouraging clinical efficacy, as well as a tolerable safety profile, with luspatercept among patients with myelodysplastic syndrome and myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.

Survival Following Post–HCT Relapse in ALL Improves With Targeted Immunotherapies

December 7th 2020

December 7, 2020 - Survival rates of adult patients with acute lymphoblastic leukemia who experience relapse following hematopoietic cell transplantation has considerably improved within the past few years, possibly due to the increased use of immunotherapy agents.

All-Oral Ixazomib Triplet Improves PFS in Select Transplant-Ineligible Newly Diagnosed Myeloma

December 7th 2020

December 7, 2020 - The addition of ixazomib to lenalidomide and dexamethasone resulted in a clinically meaningful 13.5-month improvement in the median progression-free survival of elderly patients with transplant-ineligible newly diagnosed multiple myeloma, although it did not reach statistical significance.

Daratumumab Combo Improved Response Rates for Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma

December 7th 2020

Daratumumab plus lenalidomide, bortezomib, and dexamethasone followed by daratumumab and lenalidomide maintenance showed a statistically significant improvement in response rates and depth of responses when compared to RVd followed by lenalidomide maintenance for patients with transplant-eligible newly diagnosed multiple myeloma.

Negrin Shines Light on the Orca-T Story in GVHD

December 7th 2020

What started out as a journey to better understand regulatory T cells has now led to an intriguing approach with an investigational cell therapy designed to prevent the risk of graft-versus-host disease and to improve relapse-free survival rates in patients undergoing hematopoietic stem cell transplantation.

Glofitamab Demonstrates High CR Rate in Relapsed/Refractory NHL

December 7th 2020

December 7, 2020 — The T-cell–engaging bispecific antibody glofitamab elicited a high rate of complete responses, when given in a step-up dosing schedule, in patients with relapsed/refractory non-Hodgkin lymphoma.

Subcutaneous Daratumumab Combo Improves PFS in Relapsed/Refractory Multiple Myeloma

December 7th 2020

December 7, 2020 - The addition of subcutaneous daratumumab to pomalidomide and dexamethasone significantly reduced the risk of progression or death by 37%, compared with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma who had received ≥1 prior line of therapy.

African-American Race: An Independent Predictor of Poor Survival in Younger Patients With AML?

December 7th 2020

December 6, 2020 - Self-reported black race was found to be the most important factor associated with poor survival in patients under 60 years old with acute myeloid leukemia.

Ide-Cel Delivers Clinically Meaningful HRQoL Benefits in Triple-Class Exposed Relapsed/Refractory Myeloma

December 6th 2020

Treatment with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel was found to yield clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.

CELMoD CC-92480/Dexamethasone Combo Shows Early Activity in Relapsed/Refractory Myeloma

December 6th 2020

CC-92480, a novel oral cereblon E3 ligase modulator agent, plus dexamethasone demonstrated immunomodulatory activity across all dose levels examined in patients with relapsed/refractory multiple myeloma, according to data from the first portion of the ongoing phase 1 CC-92480-MM-001 trial presented during the 2020 ASH Annual Meeting & Exposition.

Odronextamab Is Active With Acceptable Benefit–Risk Profile in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

December 6th 2020

December 6, 2020 - Odronextamab, is a novel CD20xCD3 bispecific antibody, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

Orca-T Exhibits GVHD Preventive Potential in High-Risk Hematologic Malignancies

December 6th 2020

December 6, 2020 - Orca-T, a precision Treg-engineered donor product, demonstrated preventive potential for graft-versus-host disease, with less immunosuppression, compared with the standard of care in patients with high-risk hematologic malignancies who underwent hematopoietic stem cell transplantation.

Dr. Cutler on the Results of the ROCKstar Study in cGVHD

December 6th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses the results of the ROCKstar study in chronic graft-versus-host disease.

Cilta-Cel Improves HRQoL in Relapsed/Refractory Multiple Myeloma

December 6th 2020

Ciltacabtagene autoleucel was found to elicit clinically meaningful improvements in health-related quality of life in patients with relapsed/refractory multiple myeloma, and this benefit may become even more pronounced as responses to treatment deepen over time, according to data from the CARTITUDE-1 study presented during the 2020 ASH Annual Meeting & Exposition.

IGM-2323 Shrinks Tumors in Advanced B Cell Malignancies

December 6th 2020

December 6, 2020 - The bispecific IgM antibody IGM-2323 shrank tumors in 9 of 14 patients with CD20-positive, relapsed/refractory non-Hodgkin lymphomas in preliminary results from a phase 1 clinical trial presented at the 2020 ASH Annual Meeting

Sabatolimab Showcases Similar Pharmacokinetics Across 400- and 800-mg Doses in MDS/AML

December 6th 2020

Sabatolimab demonstrated comparable pharmacokinetic activity at doses of 200 mg every 2 weeks and 800 mg every 4 weeks in combination with hypomethylating agents in patients with acute myeloid leukemia and myelodysplastic syndrome.

Cevostamab Monotherapy Safe, Highly Active in Heavily Pretreated Relapsed/Refractory Myeloma

December 6th 2020

December 6, 2020 - The first-of-its-kind FcRH5xCD3 bispecific antibody cevostamab demonstrated a manageable safety profile with an overall response rate of 53% in heavily pretreated patients with relapsed/refractory multiple myeloma who received active doses.

CD47-Directed TTI-622 Elicits Early Efficacy Signals in Relapsed/Refractory Lymphoma

December 6th 2020

December 6, 2020 — TTI-622, an investigational CD47 inhibitor, showed preliminary signs of clinical activity with a manageable safety profile among patients with relapsed/refractory lymphoma.